The ISAR-SHOCK trial was done to evaluate the safety and efficacy of the Impella 2.5 versus the IAPB in patients with cardiogenic shock due to acute myocardial infarction. Patients were randomized to support from an IABP (n=13) or an Impella (n=12). One patient died before implantation of a device.